TB-500 (10mg)

This is a single-compound TB-500 research product supplied as a nominal 10mg lyophilised vial. The published Janoshik report labels its tested analyte “TB-500 (TB4)”. It does not provide an amino-acid sequence, so the product name alone does not establish whether a particular full-length thymosin beta-4 or fragment study applies to this material.

No BPC-157 is listed as an ingredient in this single-compound TB-500 product. For a vial that intentionally combines both compounds, see the separate BPC-157 + TB-500 blend.

TB500 and TB-500 are spelling variations used for this listing. Thymosin beta-4 and its fragments require more precise identification: a 2012 analytical study identified the acetylated 17–23 fragment in a product called TB-500. That study did not analyse our product. Compare the actual sequence and batch documentation before treating names as chemically interchangeable.

Mechanism claims depend on the exact peptide studied. Full-length thymosin beta-4 and short fragments are different preparations, so evidence about cell movement or tissue repair cannot automatically be transferred between them. The public report for this product gives an analyte name, measured amount and purity, but no sequence or mechanism testing.

This product is supplied for laboratory research, with no established clinical injury-treatment benefit for this vial. References to muscle, tendon or ligament studies should identify the exact compound, research model and formulation. A product name or purity result cannot establish effectiveness for an injury.

This listing supplies TB-500 as a single compound. The BPC-157 + TB-500 10mg blend, commonly called the Wolverine Stack, combines two compounds in one vial; its 10mg label refers to the combined nominal content. BPC-157 10mg is also available as a separate research product. Compare each product’s composition and published report.

The public Janoshik report records 10.41mg of “TB-500 (TB4)” and 98.240% purity in the tested sample, analysed on 6 May 2026. The nominal product size is 10mg. Sample amount and purity are separate measurements; this report does not demonstrate clinical benefit, sterility or the result for every vial. See the CoA library for the published document.

TB-500 is supplied as a lyophilized powder and should be reconstituted with bacteriostatic water (BAC water) immediately before use. Inject the BAC water slowly into the vial, directing the stream down the inside wall. Gently swirl to dissolve — do not shake. Once reconstituted, store at 2–8°C and use within 8–12 weeks. For a full step-by-step walkthrough, see our complete peptide reconstitution guide.

Store lyophilized TB-500 vials at -20°C, away from light and moisture. After reconstitution with BAC water, refrigerate at 2–8°C and use within 8–12 weeks. Do not freeze the reconstituted solution.

TB-500 (10mg) is available through Aussie Peptides with fast domestic shipping to all Australian states and territories. Every vial is dispatched from within Australia — no customs delays, no international freight uncertainty. Each batch undergoes third-party analysis and the Certificate of Analysis is available to view in our CoA library.

TB-500 (10mg) is priced at $119.99 per vial at Aussie Peptides. All orders ship domestically within Australia, and batch CoAs are available in our CoA library.